|4Oct 23, 4:25 PM ET

ADMA BIOLOGICS, INC. 4

4 · ADMA BIOLOGICS, INC. · Filed Oct 23, 2013

Insider Transaction Report

Form 4
Period: 2013-10-22
Transactions
  • Purchase

    Common Stock

    2013-10-22$8.50/sh+411,765$3,500,0033,620,143 total(indirect: By Aisling Capital II, LP)
Footnotes (2)
  • [F1]After giving effect to the stock split at a ratio of 1.27-for-1 effected by ADMA Biologics, Inc. on April 4, 2013.
  • [F2]The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling Capital Partners, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners and the Managers share voting and dispositive power over the shares directly held by Aisling.

Documents

1 file
  • 4
    es1301172_4-adma.xmlPrimary

    OWNERSHIP DOCUMENT